Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials
ElKhalifa D, Al-Ziftawi N, Awaisu A, Alali F, Khalil A
Frontiers in oncology · 11 citations
How it was studied
- Design
- Systematic review (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
- Intake measured by
- Not stated
Who paid for it
- Funding
- Independent funding
- University or hospital
- Qatar University
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2023-11-24 · Front Oncol · vol. 13 · p. 1251895
- Publisher
- Frontiers Media
- Cited
- 19 citations · more than 61% of similar papers · 0.6× the field average
- References
- 63 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Genomics, phytochemicals, and oxidative stress · Curcumin's Biomedical Applications · Kruppel-like factors research
- Keywords
- Medicine, Adverse effect, Oncology, Meta-analysis, Prostate cancer, Internal medicine, Cancer, Tolerability, Systematic review, Randomized controlled trial, Clinical trial, Pancreatic cancer, Sulforaphane, MEDLINE, Cancer research
5 authors
From QA
- Dana H. ElkhalifaQatar Orthopaedic and Sports Medicine Hospital
- Nour Hisham Al-Ziftawi
- Ahmed AwaisuQatar University
- Feras Qasem AlaliQatar University
- Ashraf A. Khalil · correspondingQatar University
Abstract
Objectives
This paper presents a systematic review aimed at assessing the therapeutic potential of sulforaphane (SFN) in the treatment of diverse cancer types.
Methods
Following Cochrane guidelines for systematic reviews, we conducted an exhaustive search of electronic databases up to May 12, 2023, encompassing PubMed, Cochrane, Embase, Web of Science, Google Scholar, Natural Medicines, ProQuest, ClinicalTrials.gov, and ICTRP. Studies were included if they were human-based RCTs involving cancer patients where SFN was the primary experimental treatment. The Cochrane Risk of Bias tool for RCTs (RoB2) was used for quality assessment.
Results
Eight studies investigating the efficacy and safety of SFN in prostate cancer (PCa), breast cancer, pancreatic cancer, and melanoma were identified and included in the review. The dosing regimens were variable and inconsistent across the studies. SFN treatment led to statistically significant alterations in several vital genes and histological biomarkers across the studies. However, it did not impact some other key genes. Although not statistically significant, SFN improved overall survival in pancreatic cancer patients. The results on prostate-specific antigen (PSA) were inconsistent in PCa. None of the studies reported significant differences between SFN and comparative controls in terms of adverse events.
Conclusion
SFN has emerged as a promising and safe therapeutic agent for diverse cancer types. Nevertheless, the high levels of methodological and clinical heterogeneity across the included studies precluded the possibility of conducting meta-analyses. Further robust clinical investigations to conclusively ascertain the chemotherapeutic potential of SFN in the management of various cancer forms are needed.
Systematic review registration
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022323788, identifier CRD42022323788.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.